Alessia Indrieri


Area of interest:

Dr. Alessia Indrieri is a Tenured CNR Researcher, and a Principal Investigator at the Telethon Institute of Genetics Medicine (TIGEM), Pozzuoli, Italy.

She graduated in Biological Science, University of Naples “Federico II” in 2005, and received her PhD in Molecular Medicine from the European School of Molecular Medicine (SEMM) in 2011. During post-doctoral fellow at the TIGEM, she focuses her research interest on the study and therapy of Mitochondrial Disorders and of Mitochondrial-associated neurodegenerations. Moreover, she acquired a strong expertise in the biology of non-coding RNA and in their application in disease therapy. In 2019 she became a tenured scientist at the Institute of Genetic and Biomedical Research (IRGB), and recently started her independent laboratory at the TIGEM in the Molecular Therapy Program.

The main interest of her laboratory is to develop and validate new therapeutic strategies to treat mitochondrial-associated neurodegeneration in a mutation-independent manner.

In particular, strategies aimed to increase mitochondrial turnover will be applied in models of rare diseases such as mitochondrial Optic Neuropathies, as well as in model of common disorders such as Glaucoma, Diabetic Retinopathy and Parkinson’s Disease.

Most significant publications:


Barbato, A; Iuliano, A; Volpe, M; DÁlterio, R; Brillante, S; Massa, F; Cegli, R De; Carrella, S; Salati, M; Russo, A; Russo, G; Riccardo, S; Cacchiarelli, D; Capone, M; Madonna, G; Ascierto, P A; Franco, B; Indrieri, A; Carotenuto, P

Integrated Genomics Identifies miR-181/ŦFAM Pathway as a Critical Đriver of Đrug Resistance in Melanoma Journal Article

In: Int J Mol Sci, 22 (4), 2021.



Indrieri, A; Carrella, S; Carotenuto, P; Banfi, S; Franco, B

Ŧhe Pervasive Role of the miR-181 Family in Đevelopment, Neurodegeneration, and Cancer Journal Article

In: Int J Mol Sci, 21 (6), 2020.


Carrella, S; Indrieri, A; Franco, B; Banfi, S

Mutation-Independent Ŧherapies for Retinal Điseases: Focus on Gene-Based Approaches Journal Article

In: Front Neurosci, 14 , pp. 588234, 2020.


Indrieri, A; Pizzarelli, R; Franco, B; Leonibus, E De

Đopamine, Alpha-Synuclein, and Mitochondrial Đysfunctions in Parkinsonian Eyes Journal Article

In: Front Neurosci, 14 , pp. 567129, 2020.


Marrocco, E; Indrieri, A; Esposito, F; Tarallo, V; Carboncino, A; Alvino, F G; Falco, S De; Franco, B; Risi, M De; Leonibus, E De

α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells Journal Article

In: Sci Rep, 10 (1), pp. 9619, 2020.



Indrieri, A; Carrella, S; Romano, A; Spaziano, A; Marrocco, E; Fernandez-Vizarra, E; Barbato, S; Pizzo, M; Ezhova, Y; Golia, F M; Ciampi, L; Tammaro, R; Henao-Mejia, J; Williams, A; Flavell, R A; Leonibus, E De; Zeviani, M; Surace, E M; Banfi, S; Franco, B

miR-181a/b downregulation exerts a protective action on mitochondrial disease models Journal Article

In: EMBO Mol Med, 11 (5), 2019.



Indrieri, A; Grimaldi, C; Zucchelli, S; Tammaro, R; Gustincich, S; Franco, B

Synthetic long non-coding RNAs [SINEUPs] rescue defective gene expression in vivo Journal Article

In: Sci Rep, 6 , pp. 27315, 2016.



Indrieri, A; Conte, I; Chesi, G; Romano, A; Quartararo, J; Tatè, R; Ghezzi, D; Zeviani, M; Goffrini, P; Ferrero, I; Bovolenta, P; Franco, B

Ŧhe impairment of ĦCCS leads to MLS syndrome by activating a non-canonical cell death pathway in the brain and eyes Journal Article

In: EMBO Mol Med, 5 (2), pp. 280–293, 2013.



Indrieri, A; van Rahden, V A; Tiranti, V; Morleo, M; Iaconis, D; Tammaro, R; DÁmato, I; Conte, I; Maystadt, I; Demuth, S; Zvulunov, A; Kutsche, K; Zeviani, M; Franco, B

Mutations in COX7B cause microphthalmia with linear skin lesions, an unconventional mitochondrial disease Journal Article

In: 91 (5), pp. 942–949, 2012.